The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease
Open accessAbstract
BACKGROUND: Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease. METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini-Mental State Examination [SMMSE, on which scores range from 0 to 30, with higher scores indicating better cognitive function]) to continue donepezil, discontinue donepezil, discontinue donepezil and start memantine, or continue donepezil and start memantine. Patients received the study treatment for 52 weeks. The coprimary outcomes were scores on the SMMSE and on the Bristol Activities of Daily Living Scale (BADLS, on which scores range from 0 to 60, with higher scores indicating greater impairment). The minimum clinically important differences were 1.4 points on the SMMSE and 3.5 points on the BADLS. RESULTS: Patients assigned to continue donepezil, as compared with those assigned to discontinue donepezil, had a score on the SMMSE that was higher by an average of 1.9 points (95% confidence interval [CI], 1.3 to 2.5) and a score on the BADLS that was lower (indicating less impairment) by 3.0 points (95% CI, 1.8 to 4.3) (P<0.001 for both comparisons). Patients assigned to receive memantine, as compared with those assigned to receive memantine placebo, had a score on the SMMSE that was an average of 1.2 points higher (95% CI, 0.6 to 1.8; P<0.001) and a score on the BADLS that was 1.5 points lower (95% CI, 0.3 to 2.8; P=0.02). The efficacy of donepezil and of memantine did not differ significantly in the presence or absence of the other. There were no significant benefits of the combination of donepezil and memantine over donepezil alone. CONCLUSIONS: In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months. (Funded by the U.K. Medical Research Council and the U.K. Alzheimer's Society; Current Controlled Trials number, ISRCTN49545035.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In moderate and severe AD, short-term efficacy of memantine monotherapy compared with placebo is reported in several RCTs of 12 to 50 weeks duration and supported by meta-analyses.”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new look at the statistical model identification
Akaike, H. (1974) · IEEE Transactions on Automatic Control · doi:10.1109/tac.1974.1100705 · Cited by 51,879
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700
ANew Look at the Statistical Model Identification
AKAlKE, H. (2011) · Cited by 4,177
The Validity of Two Versions of the GHQ in the WHO Study of Mental Illness in General Health Care
GOLDBERG, D. P., GATER, R., SARTORIUS, N., USTUN, T. B., PICCINELLI, M., GUREJE, O., & RUTTER, C. (1997) · Psychological Medicine · doi:10.1017/s0033291796004242 · Cited by 3,657
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Smith, S. C., Lamping, D. L., Banerjee, S., Harwood, R., Foley, B., Smith, P. B., Cook, J., Murray, J., Prince, M. J., Levin, E., et al. (2005) · Health Technology Assessment · doi:10.3310/hta9100 · Cited by 651
Flagged first, then by citations
1 of the 31 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Areosa SA, 2005, Cochrane Database Syst Rev, 3, CD003154
- Smith SC, 2005, Health Technol Assess, 9, 1
- 10.1097/00005650-200305000-00004 · DOI
Cited by
Sorted by citations
Items 101–200 of 787
Memantine: Updating a rare success story in pro-cognitive therapeutics
Tari, P. K., Parsons, C. G., Collingridge, G. L., & Rammes, G. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109737 · Cited by 78
Webster, L., Groskreutz, D., Grinbergs‐Saull, A., Howard, R. J., O'Brien, J. T., Mountain, G. A., Banerjee, S., Woods, B. T., Perneczky, R., Lafortune, L., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21260 · Cited by 75
Potential drug–drug interactions in Alzheimer patients with behavioral symptoms
Monzani, F., Pasqualetti, G., Tognini, S., Calsolaro, V., & Polini, A. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s87466 · Cited by 76
The Role of Genetics in Advancing Precision Medicine for Alzheimer’s Disease—A Narrative Review
Freudenberg‐Hua, Y., Li, W., & Davies, P. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00108 · Cited by 80
Prions activate a p38 MAPK synaptotoxic signaling pathway
Fang, C., Wu, B., Le, N. T. T., Imberdis, T., Mercer, R. C. C., & Harris, D. A. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007283 · Cited by 74
Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders
Malar, D. S., Thitilertdecha, P., Ruckvongacheep, K. S., Brimson, S., Tencomnao, T., & Brimson, J. M. (2023) · CNS Drugs · doi:10.1007/s40263-023-01007-6 · Cited by 77
Rabins, P. V., Rovner, B. W., Rummans, T. A., Schneider, L. S. S., & Tariot, P. N. (2017) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.15106 · Cited by 77
Molino, I., Colucci, L., Fasanaro, A. M., Traini, E., & Amenta, F. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/925702 · Cited by 73
Oh, E. S., & Rabins, P. V. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201909030 · Cited by 77
Ehret, M. J., & Chamberlin, K. W. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.05.510 · Cited by 70
Memantine ER/Donepezil: A Review in Alzheimer’s Disease
Greig, S. L. (2015) · CNS Drugs · doi:10.1007/s40263-015-0287-2 · Cited by 69
Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients
Bogolepova, A. N., Васенина, Е. Е., Gomzyakova, N. A., Gusev, E. I., Dudchenko, N. G., Emelin, А. Y., Zalutskaya, N. M., Isaev, R. I., Kotovskaya, Y. V., Levin, O. S., et al. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20211211036 · Cited by 72
Bowen, R. L., Perry, G. L., Xiong, C., Smith, M. A., & Atwood, C. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-141626 · Cited by 69
Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease
Baseman, A. S., Häger, K., Nye, J. S., Brashear, R. H., Han, J., Sano, M., Davis, B. M., & Richards, H. M. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s57909 · Cited by 69
Kingston, A., Davies, K., Collerton, J. C., Robinson, L. A., Duncan, R. C., Bond, J., Kirkwood, T. B. L., & Jagger, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088016 · Cited by 68
Impact of an intervention to support hearing and vision in dementia: The SENSE‐Cog Field Trial
Leroi, I., Simkin, Z., Hooper, E., Wolski, L., Abrams, H. B., Armitage, C. J., Camacho, E. M., Charalambous, A. P., Collin, F., Constantinidou, F., et al. (2019) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5231 · Cited by 67
Pharmacological treatment of dementia
Schwarz, S. T., Froelich, L., & Burns, A. S. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328358e4f2 · Cited by 69
Maurice, T. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.09.020 · Cited by 69
Cummings, J. L., Geldmacher, D., Farlow, M. R., Sabbagh, M. N., Christensen, D. D., & Betz, P. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12076 · Cited by 64
Tan, C. O., & Taylor, J. A. (2013) · Experimental Physiology · doi:10.1113/expphysiol.2013.072355 · Cited by 70
Cunningham, E. L., McGuinness, B., Herron, B. M., & Passmore, A. P. (2015) · PubMed · Cited by 68
Koch, G., Motta, C., Bonnı̀, S., Pellicciari, M. C., Picazio, S., Casula, E. P., Maiella, M., Lorenzo, F. D., Ponzo, V., Ferrari, C., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.10372 · Cited by 64
Knapp, M. R. J., King, D., Romeo, R., Adams, J., Baldwin, A., Ballard, C. G., Banerjee, S., Barber, R., Bentham, P., Brown, R. G., et al. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4583 · Cited by 63
Maxwell, C. J., Stock, K. J., Seitz, D. P., & Herrmann, N. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405901203 · Cited by 64
Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Dwomoh, L., Tejeda, G. S., & Tobin, A. B. (2022) · Neuronal Signaling · doi:10.1042/ns20210004 · Cited by 60
Samadi, A., Estrada, M., Pérez, C., Rodrı́guez-Franco, M. I., Iriepa, I., Moraleda, I., Chioua, M., & Marco, J. L. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.09.030 · Cited by 62
Xu, Y., Au, N. P. B., & Ma, C. H. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.896852 · Cited by 68
Yang, F. B., Dawes, P., Leroi, I., & Gannon, B. (2017) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4771 · Cited by 60
Advances on Therapeutic Strategies for Alzheimer’s Disease: From Medicinal Plant to Nanotechnology
Hassan, N. A., Alshamari, A. K., Hassan, A. A., Elharrif, M. G., Alhajri, A. M., Sattam, M., & Khattab, R. R. (2022) · Molecules · doi:10.3390/molecules27154839 · Cited by 68
Evaluation and Management of the Elderly Patient Presenting with Cognitive Complaints
Hildreth, K. L., & Church, S. D. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.11.006 · Cited by 66
BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer’s disease
Burke, R. M., Norman, T. A., Haydar, T. F., Slack, B. E., Leeman, S. E., Blusztajn, J. K., & Mellott, T. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319297110 · Cited by 59
Roles and Mechanisms of Axon-Guidance Molecules in Alzheimer’s Disease
Zhang, L., Qi, Z., Li, J., Li, M., Du, X., Wang, S., Zhou, G., Xu, B., Liu, W., Xi, S., et al. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02311-2 · Cited by 58
Herrmann, N., O'Regan, J., Ruthirakuhan, M. T., Kiss, A., Eryavec, G. M., Williams, E., & Lanctôt, K. L. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.08.019 · Cited by 59
Kishi, T., Matsunaga, S., & Iwata, N. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s142839 · Cited by 59
An evaluation of memantine ER + donepezil for the treatment of Alzheimer’s disease
Calhoun, A. J., King, C., Khoury, R., & Grossberg, G. T. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1519022 · Cited by 62
Steiner, G. Z., Ee, C., Dubois, S., MacMillan, F., George, E. S., McBride, K. A., Karamacoska, D., McDonald, K., Harley, A., Abramov, G., et al. (2020) · BMC Geriatrics · doi:10.1186/s12877-019-1410-x · Cited by 59
Couteur, D. G. L., Hilmer, S. N., Glasgow, N., Naganathan, V., & Cumming, R. G. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg006.pub2 · Cited by 59
Wang, G., Berry, S. M., Xiong, C., Hassenstab, J. J., Quintana, M., McDade, E., Delmar, P., Vestrucci, M., Sethuraman, G., Bateman, R. J., et al. (2018) · Statistics in Medicine · doi:10.1002/sim.7811 · Cited by 61
Herrmann, N., Gauthier, S. G., Boneva, N., & Lemming, O. M. (2013) · International Psychogeriatrics · doi:10.1017/s1041610213000239 · Cited by 59
Dual Inhibitors of Cholinesterases and Monoamine Oxidases for Alzheimer’S Disease
Knez, D., Sova, M., Košak, U., & Gobec, S. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0036 · Cited by 58
Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease
Herring, W. L., Gould, I. G., Fillit, H. M., Lindgren, P., Forrestal, F., Thompson, R., & Pemberton-Ross, P. J. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00273-0 · Cited by 57
Mechanistic insights and emerging therapeutic stratagems for Alzheimer’s disease
Rajendran, K., & Krishnan, U. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102309 · Cited by 59
Recent Advances in Drug Development for Alzheimer’s Disease: A Comprehensive Review
Xing, H., Yue, S., Qin, R., Du, X., Wu, Y., Zhangsun, D., & Luo, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083905 · Cited by 66
Pharmacological Treatment of Dementia: A Scoping Review of Systematic Reviews
van de Glind, E. M. M., van Enst, W. A., Munster, B. C. V., Rikkert, M. G. M. O., Scheltens, P., Scholten, R. J. P. M., & Hooft, L. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000353892 · Cited by 55
New and emerging treatments for Alzheimer’s disease
Corbett, A., Smith, J. S., & Ballard, C. G. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.43 · Cited by 58
Drugs, games, and devices for enhancing cognition: implications for work and society
Brühl, A. B., & Sahakian, B. J. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13040 · Cited by 58
Mueller, C., Perera, G., Hayes, R. D., Shetty, H., & Stewart, R. J. (2017) · Age and Ageing · doi:10.1093/ageing/afx098 · Cited by 57
Metabolic disorder in Alzheimer’s disease
Poddar, M. K., Banerjee, S., Chakraborty, A., & Dutta, D. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00673-z · Cited by 58
Matsuzono, K., Hishikawa, N., Ohta, Y., Yamashita, T., Deguchi, K., Nakano, Y., & Abe, K. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143084 · Cited by 55
Novel Multitarget-Directed Ligands Aiming at Symptoms and Causes of Alzheimer’s Disease
Więckowska, A., Wichur, T., Godyń, J., Bucki, A., Marcinkowska, M., Siwek, A., Więckowski, K., Zaręba, P., Knez, D., Głuch‐Lutwin, M., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00024 · Cited by 55
Sahakian, B. J., & Morein‐Zamir, S. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00004-8 · Cited by 55
Brancatisano, O., Baird, A., & Thompson, W. F. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01435 · Cited by 59
Drange, O. K., Smeland, O. B., Shadrin, A. A., Finseth, P. I., Witoelar, A., & Frei, O. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00220 · Cited by 57
A Longitudinal Study of Epileptic Seizures in Alzheimer's Disease
Baker, J., Libretto, T., Henley, W., & Zeman, A. Z. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01266 · Cited by 53
Blanco-Silvente, L., Capellà, D., Garre‐Olmo, J., Franch, J. V., & Cervelló, X. C. (2018) · BMC Geriatrics · doi:10.1186/s12877-018-0857-5 · Cited by 58
Rps27a might act as a controller of microglia activation in triggering neurodegenerative diseases
Khayer, N., Mirzaie, M., Marashi, S., & Jalessi, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239219 · Cited by 53
Neurodegenerative Diseases: Their Onset, Epidemiology, Causes and Treatment
Zaib, S., Javed, H., Khan, I. A., Jaber, F. T., Sohail, A., Zaib, Z., Mehboob, T., Tabassam, N., & Ogaly, H. A. (2023) · ChemistrySelect · doi:10.1002/slct.202300225 · Cited by 53
Sacuiu, S. F. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802973-2.00008-2 · Cited by 57
Shi, J., Ni, J., Lu, T., Zhang, X., Wei, M., Li, T., Liu, W., Wang, Y., Shi, Y., & Tian, J. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-2040-5 · Cited by 51
Can zebrafish be used as animal model to study Alzheimer's disease?
Santana, S., Rico, E. P., & Burgos, J. S. (2012) · Europe PMC (PubMed Central) · Cited by 51
Alzheimer disease and neuroplasticity
Koch, G., & Spampinato, D. A. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819410-2.00027-8 · Cited by 50
Immunotherapy against amyloid pathology in Alzheimer's disease
Galimberti, D., Ghezzi, L., & Scarpini, E. A. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.12.013 · Cited by 50
Qneibi, M., Bdir, S., Maayeh, C., Bdair, M., Sandouka, D., Basit, D., & Hallak, M. (2023) · Neurochemical Research · doi:10.1007/s11064-023-04032-5 · Cited by 55
Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease
Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Santamato, A., Lozupone, M., Prete, C., Greco, A., Pilotto, A., & Logroscino, G. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1092520 · Cited by 49
Treating Alzheimer’s disease using nanoparticle-mediated drug delivery strategies/systems
Roghani, A. K., Garcia, R. I., Roghani, A., Reddy, A. P., Khemka, S., Reddy, R. P., Pattoor, V., Jacob, M., Reddy, P. H., & Sehar, U. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102291 · Cited by 53
Muayqil, T. A., & Camicioli, R. M. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000343479 · Cited by 48
Non-pharmacological cognitive intervention for aging and dementia: Current perspectives
Alves, J. (2013) · World Journal of Clinical Cases · doi:10.12998/wjcc.v1.i8.233 · Cited by 48
Kucwaj‐Brysz, K., Baltrukevich, H., Czarnota-Łydka, K., & Handzlik, J. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128275 · Cited by 50
Wilkinson, D. G., Wirth, Y., & Goebel, C. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000353801 · Cited by 47
Colloca, G., Tosato, M., Vetrano, D., Topinková, E., Fialová, D., Gindin, J., der Roest, H. G. V., Landi, F., Liperoti, R., Bernabei, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046669 · Cited by 46
Thorpe, C. T., Fowler, N. R., Harrigan, K., Zhao, X., Kang, Y., Hanlon, J. T., Gellad, W. F., Schleiden, L. J., & Thorpe, J. M. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14403 · Cited by 46
Nirogi, R. V. S., Shinde, A. K., Kambhampati, R. S., Mohammed, A. R., Saraf, S. K., Badange, R. K., Bandyala, T. R., Bhatta, V., Bojja, K., Reballi, V., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01662 · Cited by 47
Policicchio, S. S. S., Ahmad, A. N., Powell, J. F., & Proitsi, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-13168-8 · Cited by 48
Cai, M., Guo, Z., Xing, G., Peng, H., Zhou, L., Chen, H., McClure, M. A., He, L., Xiong, L., He, B., et al. (2019) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000304 · Cited by 48
Parsons, C., Lim, W. Y., Loy, C. T., McGuinness, B., Passmore, P., Ward, S. A., & Hughes, C. M. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009081.pub2 · Cited by 49
Versijpt, J. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132639 · Cited by 48
A population-based study of dosing and persistence with anti-dementia medications
Brewer, L., Bennett, K., McGreevy, C., & Williams, D. J. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1483-y · Cited by 45
Francis, P. T., Parsons, C. G., & Jones, R. W. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.124 · Cited by 47
Kröger, E., Wilchesky, M., Marcotte, M., Voyer, P., Morin, M., Champoux, N., Monette, J., Aubin, M., Durand, P. J., Verreault, R., et al. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.04.002 · Cited by 44
Walach, H., & Loef, M. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.03.027 · Cited by 47
Alzheimer Disease Pharmacologic Treatment and Treatment Research
Schneider, L. S. (2013) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000429180.60095.d0 · Cited by 45
Pharmacological interventions for apathy in Alzheimer's disease
Ruthirakuhan, M. T., Herrmann, N., Abraham, E. H., Chan, S., & Lanctôt, K. L. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012197.pub2 · Cited by 113
Apathy and Motivation: Biological Basis and Drug Treatment
Costello, H., Husain, M., & Roiser, J. P. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022423-014645 · Cited by 51
Liu, W., Li, Y., Zhao, T., Gong, M., Wang, X., Zhang, Y., Xu, L., Li, W., Li, Y., & Jia, J. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102534 · Cited by 46
Alzheimer’s Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review
Knorz, A. L., & Quante, A. (2021) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887211044746 · Cited by 46
Gareri, P., Putignano, D., Castagna, A., Cotroneo, A. M., Palo, G. D., Fabbo, A., Forgione, L., Giacummo, A., Lacava, R., Marino, S., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132735 · Cited by 42
Emerging treatments for Alzheimer’s disease for non-amyloid and non-tau targets
Khan, A., Corbett, A., & Ballard, C. G. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1326818 · Cited by 42
Abu‐Dief, A. M., Said, M. A., Elhady, O. M., AL-Abdulkarim, H. A., Alzahrani, S. O., Eskander, T. N. A., & El‐Remaily, M. A. E. A. A. A. (2023) · Applied Organometallic Chemistry · doi:10.1002/aoc.7162 · Cited by 44
Type 3 diabetes and metabolic reprogramming of brain neurons: causes and therapeutic strategies
Meng, X., Zhang, H., Zhao, Z., Li, S., Zhang, X., Guo, R., Li, H., Yuan, Y., Li, W., Song, Q., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01101-z · Cited by 47
Chiu, M., & Fan, L. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s45143 · Cited by 41
Hoque, A., Hossain, M. I., Ameen, S. S., Ang, C., Williamson, N. A., Ng, D. C. H., Chüeh, A. C., Roulston, C. L., & Cheng, H. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.009 · Cited by 42
Shao, Z. (2015) · PubMed Central · Cited by 40
Provensi, G., Costa, A., Passani, M. B., & Blandina, P. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.06.010 · Cited by 39
Dodd, K., Watchman, K., Janicki, M. P., Coppus, A. M. W., Gaertner, C., Fortea, J., Santos, F. H., Keller, S. M., & Strydom, A. (2017) · Aging & Mental Health · doi:10.1080/13607863.2017.1373065 · Cited by 43
Bullain, S., & Doody, R. S. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15023 · Cited by 40
Armijos, C., Gilardoni, G., Amay, L., Lozano, A., Bracco, F., Ramírez, J., Bec, N., Larroque, C., Finzi, P. V., & Vidari, G. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.09.049 · Cited by 38
Charting a path toward combination therapy for Alzheimer’s disease
Stephenson, D., Perry, D., Bens, C., Bain, L. J., Berry, D., Krams, M., Sperling, R., Dilts, D., Luthman, J., Hanna, D., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995168 · Cited by 37
de Oliveira, F. F., Bertolucci, P. H. F., Chen, E., & Smith, M. D. A. C. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.10.015 · Cited by 36
Tsoi, K. K. F., Chan, J. Y. C., Leung, N. W. Y., Hirai, H. W., Wong, S. Y. S., & Kwok, T. C. Y. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.05.015 · Cited by 37
A geroscience motivated approach to treat Alzheimer’s disease: Senolytics move to clinical trials
Gonzales, M. M., Krishnamurthy, S., Garbarino, V. R., Daeihagh, A. S., Gillispie, G. J., Deep, G., Craft, S., & Orr, M. E. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111589 · Cited by 37
Metadata
- Authors
- Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., Hughes, A., Jacoby, R., Jones, R., Jones, R., McKeith, I., Macharouthu, A., O'Brien, J., Passmore, P., Sheehan, B., Juszczak, E., Katona, C., Hills, R., Knapp, M., Ballard, C., Brown, R., Banerjee, S., Onions, C., Griffin, M., Adams, J., Gray, R., Johnson, T., Bentham, P., & Phillips, P.
- Affiliations
- King's College London (GB)
- Churchill Hospital (GB)
- University of Leicester (GB)
- Whiston Hospital (GB)
- Newcastle University (GB)
- University of Manchester (GB)
- Fulbourn Hospital (GB)
- University of Oxford (GB)
- Inverclyde Royal Hospital (GB)
- Crichton Royal Hospital (GB)
- Queen's University Belfast (GB)
- University of Warwick (GB)
- University College London (GB)
- University of Wales (GB)
- Avon and Wiltshire Mental Health Partnership NHS Trust (GB)
- University of Cambridge (GB)
- Queen Elizabeth Hospital Birmingham (GB)
- ORCID
- Howard, Robert
- McShane, Rupert
- Ritchie, Craig
- Baldwin, Ashley
- Barber, Robert
- Burns, Alistair
- Dening, Tom
- Findlay, David
- Holmes, Clive
- Jones, Roy
- McKeith, Ian
- Macharouthu, Ajay
- O'Brien, John
- Passmore, Peter
- Sheehan, Bart
- Juszczak, Edmund
- Katona, Cornelius
- Hills, Robert
- Knapp, Martin
- Ballard, Clive
- Brown, Richard
- Banerjee, Sube
- Gray, Richard
- Johnson, Tony
- Bentham, Peter
- Phillips, Patrick
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-08
- Volume
- 366
- Issue
- 10
- Pages
- 893-903
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2151585937
- Cited by
- 782
- References
- 31
- Citations by year
- 2026: 43 · 2025: 49 · 2024: 44 · 2023: 58 · 2022: 51 · 2021: 48 · 2020: 45 · 2019: 58 · 2018: 47 · 2017: 55 · 2016: 54 · 2015: 54 · 2014: 59 · 2013: 74 · 2012: 40
- FWCI
- 52.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion, other-oa)
- Warwick Research Archive Portal (University of Warwick) (acceptedVersion)
- Leicester Research Archive (University of Leicester) (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Figshare (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Sussex Research Online (University of Sussex) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Alzheimer's Society
- King's College London
- Medical Research Council
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, donepezil, memantine, cholinesterase inhibitors, NMDA receptor antagonists, combination therapy, cognitive function, activities of daily living, functional disability, treatment continuation, community-dwelling patients, minimal clinically important difference, treatment discontinuation
- MeSH terms
- Donepezil, Aged, Aged, 80 and over, Alzheimer Disease, Cholinesterase Inhibitors, Double-Blind Method, Drug Synergism, Drug Therapy, Combination, Female, Humans, Indans, Male, Memantine, Patient Dropouts, Piperidines, Psychological Tests, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Excitatory Amino Acid Antagonists, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
